Science News
from research organizations

New Oral Drug Shrinks Lung Cancers Before Surgery, Researchers Report

Date:
September 18, 2008
Source:
European Society for Medical Oncology
Summary:
Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, researchers report.
Share:
       
FULL STORY

Pazopanib, a new oral angiogenesis inhibitor, has demonstrated interesting activity in difficult to treat non-small-cell lung cancer, US researchers report.

In a phase II trial, 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumor size shrink by up to 85%.

"This is a positive result that will be explored further," said Prof. Nasser Altorki from Weil Medical College of Cornell University in New York.

"To my knowledge, no other results on the effect of angiogenesis inhibitors in early stage operable lung cancer have been published," he said. "The results presented here with pazopanib indicate a highly active drug in this setting and further development in lung cancer is underway to fully understand the value of this drug in this disease."


Story Source:

The above post is reprinted from materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "New Oral Drug Shrinks Lung Cancers Before Surgery, Researchers Report." ScienceDaily. ScienceDaily, 18 September 2008. <www.sciencedaily.com/releases/2008/09/080916101030.htm>.
European Society for Medical Oncology. (2008, September 18). New Oral Drug Shrinks Lung Cancers Before Surgery, Researchers Report. ScienceDaily. Retrieved June 30, 2015 from www.sciencedaily.com/releases/2008/09/080916101030.htm
European Society for Medical Oncology. "New Oral Drug Shrinks Lung Cancers Before Surgery, Researchers Report." ScienceDaily. www.sciencedaily.com/releases/2008/09/080916101030.htm (accessed June 30, 2015).

Share This Page: